Delivery Order SPE2DB22D3016-SPE2DB26FAAP1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,191.84 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on August 21, 2025, with an ultimate completion date of August 22, 2025. This firm fixed price delivery order, which was competitively awarded without set-aside designation, is to be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Naloxone is a critical opioid antagonist medication used in emergency medical response and...
- The Defense Logistics Agency awarded a $23,532.89 delivery order to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on May 16, 2025, with a completion date of May 19, 2025. This competitively awarded, firm fixed-price contract reflects no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $10,266.71 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray. This contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 18, 2025. The product will be delivered to a location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,820.47 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order represents a non-set-aside award, indicating it was competitively awarded. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. Naloxone is a critical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,189.90 for Naloxone HCl 4 mg nasal spray on September 26, 2025, with an ultimate completion date of September 29, 2025. This firm fixed-price delivery order is not set-aside and will be performed in Conshohocken, Pennsylvania, where the awardee maintains its corporate headquarters. The product represents critical medical supply for overdose reversal, which supports the agency's pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Naloxone HCL 4 mg nasal spray in a quantity of 2 units. This contract is valued at $1,135.68 with a firm fixed price structure and an ultimate completion date of September 2, 2025. The award was competitively procured with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $4,507.14 for Naloxone HCL 4 mg nasal spray on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete in open federal...
- The Defense Logistics Agency awarded a $3,984.02 delivery order to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray on August 7, 2025, with completion targeted for August 8, 2025. This is a firm fixed price, non-set-aside contract utilizing a competitive award process. The contractor will perform this delivery order from its Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $5,353.00 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray (2-count units) on October 21, 2025, with an ultimate completion date of October 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Naloxone is a critical emergency medication used to reverse opioid...
- The Defense Logistics Agency awarded a delivery order valued at $17,364.04 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray on June 18, 2025, with an ultimate completion date of June 20, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement under the defense medical...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FAAP1Delivery Order
The Defense Logistics Agency awarded a $3,865.62 delivery order to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on October 24, 2025, with an ultimate completion date of October 27, 2025. This firm fixed-price contract, which was not set-aside and awarded competitively, will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The naloxone nasal spray delivery supports the federal government's opioid overdose response capabilities and represents a routine pharmaceutical procurement through the Defense Logistics Agency's medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves critical federal medical procurement needs across military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical commodities, and this award reflects the company's ongoing role in supporting the Defense Health Agency and broader federal healthcare requirements through competitively awarded contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 10/24/25 |